Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $19.73

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $20.20.

A number of analysts have recently weighed in on BCYC shares. JMP Securities set a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial assumed coverage on Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 price objective for the company. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Citizens Jmp lifted their price target on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Friday, October 31st.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 10,989 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the sale, the chief executive officer directly owned 618,996 shares in the company, valued at $3,998,714.16. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Alethia Young sold 4,334 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.49, for a total transaction of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares of the company’s stock, valued at $565,155.69. This represents a 4.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 38,029 shares of company stock worth $251,966 over the last 90 days. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its stake in shares of Bicycle Therapeutics by 156.5% in the first quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock valued at $3,850,000 after purchasing an additional 276,671 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Bicycle Therapeutics in the 1st quarter valued at $214,000. Woodline Partners LP bought a new position in shares of Bicycle Therapeutics during the 1st quarter worth about $3,088,000. Janney Montgomery Scott LLC bought a new position in shares of Bicycle Therapeutics during the 2nd quarter worth about $697,000. Finally, Tybourne Capital Management HK Ltd. boosted its position in shares of Bicycle Therapeutics by 72.4% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock valued at $6,907,000 after acquiring an additional 417,400 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

BCYC opened at $7.00 on Tuesday. The company has a market cap of $485.59 million, a PE ratio of -1.93 and a beta of 1.52. The stock has a 50-day moving average of $6.90 and a 200-day moving average of $7.36. Bicycle Therapeutics has a 52-week low of $6.03 and a 52-week high of $13.63.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The firm had revenue of $11.73 million during the quarter, compared to analyst estimates of $8.25 million. On average, research analysts predict that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.